Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis

Michael Lardas*, Nikos Grivas, Thomas P.A. Debray, Fabio Zattoni, Christopher Berridge, Marcus Cumberbatch, Thomas Van den Broeck, Erik Briers, Maria De Santis, Andrea Farolfi, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Shane O'Hanlon, Ann Henry, Matthew Liew, Malcolm Mason, Lisa Moris, Daniela Oprea-Lager, Guillaume PloussardOlivier Rouviere, Ivo G. Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas Wiegel, Peter Paul Willemse, Cathy Y. Yuan, Jeremy P. Grummet, Derya Tilki, Roderick C.N. van den Bergh, Thomas B. Lam, Philip Cornford, Nicolas Mottet

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

25 Citations (Scopus)
24 Downloads (Pure)

Abstract

Context: While urinary incontinence (UI) commonly occurs after radical prostatectomy (RP), it is unclear what factors increase the risk of UI development. Objective: To perform a systematic review of patient- and tumour-related prognostic factors for post-RP UI. The primary outcome was UI within 3 mo after RP. Secondary outcomes included UI at 3–12 mo and ≥12 mo after RP. Evidence acquisition: Databases including Medline, EMBASE, and CENTRAL were searched between January 1990 and May 2020. All studies reporting patient- and tumour-related prognostic factors in univariable or multivariable analyses were included. Surgical factors were excluded. Risk of bias (RoB) and confounding assessments were performed using the Quality In Prognosis Studies (QUIPS) tool. Random-effects meta-analyses were performed for all prognostic factor, where possible. Evidence synthesis: A total of 119 studies (5 randomised controlled trials, 24 prospective, 88 retrospective, and 2 case-control studies) with 131 379 patients were included. RoB was high for study participation and confounding; moderate to high for statistical analysis, study attrition, and prognostic factor measurement; and low for outcome measurements. Significant prognostic factors for postoperative UI within 3 mo after RP were age (odds ratio [OR] per yearly increase 1.04, 95% confidence interval [CI] 1.03–1.05), membranous urethral length (MUL; OR per 1-mm increase 0.81, 95% CI 0.74–0.88), prostate volume (PV; OR per 1-ml increase 1.005, 95% CI 1.000–1.011), and Charlson comorbidity index (CCI; OR 1.28, 95% CI 1.09–1.50). Conclusions: Increasing age, shorter MUL, greater PV, and higher CCI are independent prognostic factors for UI within 3 mo after RP, with all except CCI remaining prognostic at 3–12 mo. Patient summary: We reviewed the literature to identify patient and disease factors associated with urinary incontinence after surgery for prostate cancer. We found increasing age, larger prostate volume, shorter length of a section of the urethra (membranous urethra), and lower fitness were associated with worse urinary incontinence for the first 3 mo after surgery, with all except lower fitness remaining predictive at 3–12 mo.

Original languageEnglish
Pages (from-to)674-689
Number of pages16
JournalEuropean Urology Focus
Volume8
Issue number3
Early online date6 May 2021
DOIs
Publication statusPublished - May 2022

Bibliographical note

Funding Information:
Financial disclosures: Michael Lardas certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Derya Tilki has received a speaker honorarium from Astellas and a travel grant from Janssen. Erik Briers has received grant and research support from IPSEN, the European Association of Urology, and Bayer; is an ex officio board member for Europa UOMO; is an ethics committee and advisory group member for REQUITE; is a patient advisory board member for PAGMI; and is a member of SCA and EMA PCWP. Silke Gillessen has served on advisory boards for Orion, Innocrin, Clovis, Bayer, AAA International, Roche, Menarini, Sanofi, and ProteoMedix; receives company speaker honoraria from Janssen; and has served on the independent data monitoring committee for Janssen. Jeremy P. Grummet has received a speaker honorarium from Mundipharma, a travel grant from Astellas, and a research grant from Cancer Australia; and is the owner of MRI PRO Pty Ltd., an online training platform. Ann Henry participates in trials by Cancer Research UK and the National Institute of Health Research; her department receives research grants from Cancer Research UK, The Medical Research Council, and the National Institute of Health. Maria De Santis is a company consultant for Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc., ESSA, Ferring, GSK, Incyte, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, Teva, OncoGenex, and Sandoz; receives speaker honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ferring, GSK, IPSEN, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, Synthon, and Takeda; participates in trials run by the Technical University Munich, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Eisai Inc., Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SOTIO, and Cancer Research UK; participates in various trials as a member of the EORTC GU group; and has received research grants from Pierre Fabre Oncologie and travel grants from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dendreon, Ferring, GSK, IPSEN, Incyte, Janssen Cilag, Merck, MSD, Novartis, Pfizer, Pierre Fabre Oncologie, Roche, Sanofi Aventis, SeaGen, Shionogi, Synthon, Takeda, and Teva/OncoGenex. Malcolm Mason is a company consultant for Ellipses Pharma and Oncotherics. Henk van der Poel is a company consultant for Intuitive Surgical; has participated in trials for Astellas and Steba Biotech; and has received grant and research support from Astellas. Thomas B. Lam is a company consultant for and has received company speaker honoraria from Pfizer, GSK, Astellas, and IPSEN. Philip Cornford is a company consultant for Astellas, IPSEN, and Ferring; receives company speaker honoraria from Astellas, Janssen, IPSEN, and Pfizer; participates in trials run by Ferring; and receives fellowships and travel grants from Astellas and Janssen. Nicolas Mottet is a company consultant for Janssen, GE, BMS, Sanofi, and Astellas; has received speaker honoraria from Astellas, Pierre Fabre, Steba, Janssen, and Ferring; and has received fellowships and travel grants from Astellas, IPSEN, Sanofi, Janssen, and Roche. Thomas Wiegel is an advisory board member for IPSEN; receives company speaker honoraria from IPSEN and Hexal; is a member of the Janssen Steering Committee; and has participated in the ATLAS/AUO trial. The remaining authors have nothing to disclose.

Publisher Copyright:
© 2021 European Association of Urology

Fingerprint

Dive into the research topics of 'Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis'. Together they form a unique fingerprint.

Cite this